Zoomed sections from TOV-112D and TOV-81D gels demonstrating differential expression of proteins listed in Table 2

<p><b>Copyright information:</b></p><p>Taken from "Comparative proteome analysis of human epithelial ovarian cancer"</p><p>http://www.proteomesci.com/content/5/1/16</p><p>Proteome Science 2007;5():16-16.</p><p>Published online 24 Sep 2007</p><p>PMCID:PMC2072939.</p><p></p> (A) Selected TOV-112D spots with undetectable TOV-81D matching spots. (B) Selected TOV-81D spots with undetectable TOV-112D matching spots. (C) Selected spots differentially expressed with a minimum deregulation ratio of 2.0

Western blot validation of selected proteins identified by iTRAQ and/or 2DE analysis

<p><b>Copyright information:</b></p><p>Taken from "Comparative proteome analysis of human epithelial ovarian cancer"</p><p>http://www.proteomesci.com/content/5/1/16</p><p>Proteome Science 2007;5():16-16.</p><p>Published online 24 Sep 2007</p><p>PMCID:PMC2072939.</p><p></p> Equal amounts, 25 μg, of protein extracts from TOV-112D and TOV-81D cell lines were loaded onto a 12 % SDS-PAGE and processed for Western blotting with the indicated antibodies. Protein expression differences were quantified using a Chemilmager 4000 imaging system and AlphaEase software 3.3 (Alpha Innotech Corporation). The data are expressed as relative integrated density value (IDV). Each point represents the mean +/- SE from three independent experiments. Data were analysed by Student's unpaired test. Representative blots for each analysis are depicted